Lineage Cell Therapeutics (LCTX) Other financing activities (2011 - 2026)
Lineage Cell Therapeutics (LCTX) reported Other financing activities of $40000.0 for Q1 2026, up 166.67% on a YoY basis from $15000.0 in Q1 2025, and up 3900.0% quarter-over-quarter from $1000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other financing activities (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Other financing activities for 16 years, with the latest figure at $40000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 166.67% year-over-year to $40000.0; the trailing twelve-month figure through Mar 2026 stood at $41000.0 (up 173.33% YoY), and the FY2025 full-year result was $16000.0, down 30.43% from the prior year.
- Other financing activities for Q1 2026 stood at $40000.0, up from $1000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.3 million in Q2 2023, with the low at $1000.0 in Q4 2025.
- Historically, Other financing activities has averaged $545818.2 across 5 years, with a median of $40000.0 in 2026.
- Annual changes were most pronounced in 2022 — Other financing activities slumped 98.8% — and 2026, when it surged 166.67%.
- Lineage Cell Therapeutics' Other financing activities stood at $11000.0 in 2022, then soared by 11436.36% to $1.3 million in 2023, then sank by 98.19% to $23000.0 in 2024, then sank by 95.65% to $1000.0 in 2025, then soared by 3900.0% to $40000.0 in 2026.
- The last three Other financing activities figures came in at $40000.0 (Q1 2026), $1000.0 (Q4 2025), and $15000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Sep 30, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 37,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Dec 31, 2022 | 11,000.00 |
| Dec 31, 2022 | 11,000.00 |
| Sep 30, 2022 | 987,000.00 |
| Sep 30, 2022 | 987,000.00 |
| Jun 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 1.24 Mn |